NUTRIGENOMICS AND BIO-AVAILABILITY ENHANCERS AS A COMBINATION THERAPY FOR MYOSTATIN INHIBITION TO COPE WITH MUSCULAR DYSTROPHY
Author Name: Suraj D. Jadhav, Snehal S. Shinde, Smitesh S. Nalage, Ajmal J. Sande
Volume/Issue: 01/12
Country: India
DOI NO.: 08.2020-25662434 DOI Link: http://www.doi-ds.org/doilink/05.2021-55868237/UIJIR
Affiliation:
- Department of Nanoscience and Technology, Yashavantrao Chavan Institute of Science, Satara (Autonomous) 415001, Maharashtra, India
- Department of Forensic Science, Yashavantrao Chavan Institute of Science, Satara (Autonomous) 415001,Maharashtra, India
ABSTRACT
Nutrigenomics deals with epigenetic changes in human with respect to dietary intake and it can be influenced by Phyto-medicines and herbal drugs. Nutrition related complications are frequently seen in Muscular Dystrophies. Myostatin is an attenuator of skeletal muscle growth and plays a major role in muscular dystrophy, Myostatin inhibitors are being investigated as potential treatments for diseases such as muscular dystrophy. Phytochemicals such as isothiocyanates have potential to inhibit Myostatin, but phyto-drug absorption varies according to molecule structure. Bioavailability enhancers are molecules when used in combination, they enhance the absorption and bioavailability of the drug molecule in Human body. Many phytoconstituents such as Quercetin, Genistein, Piperine and Naringin exhibit bioavailability enhancer property. In this opinion article, we present Nutrigenomics and bioavailability enhancers as one of approach to target muscular dystrophy related diseases.
Key words: Nutrigenomics, Bio-availability Enhancers, Combination Therapy, Myostatin, Muscular Dystrophy etc.
No comment